GlassScriptPhysician profile
Nikhil A Jariwala
NPI 1396974309
$1,632.18
in general payments reported to CMS, 2019-2025
25 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $32.90 · 2021: $101 · 2022: $93.11 · 2023: $119 · 2024: $501 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $274.41 | 2023-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $189.46 | 2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $186.69 | 2019-2022 | |
| Amgen INC. | $131.26 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $104.18 | 2024-2025 | |
| Novo Nordisk INC | $103.89 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $75.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.71 | 2019-2024 | Farxiga |
| Heartflow, INC. | $60.96 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.02 | 2019-2025 | Jardiance |
| Abbott Laboratories | $50.00 | 2024-2025 | Triclip, Cardiomems |
| Kiniksa Pharmaceuticals International, Plc | $45.66 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $36.42 | 2023-2024 | Xarelto |
| Celgene Corporation | $32.52 | 2024 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $32.36 | 2024 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $24.40 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Boston Scientific Corporation | $21.41 | 2021 | |
| Lantheus Medical Imaging, INC. | $21.25 | 2025 | |
| Medtronic, INC. | $20.68 | 2025 | Corevalve Evolut R |
| Kestra Medical Technology Services, INC. | $19.00 | 2023 | Assure Wcd |
| Medtronic USA, INC. | $17.06 | 2019 | |
| Irhythm Technologies, INC. | $16.64 | 2023 | Zio Xt Patch |
| Pfizer INC. | $15.57 | 2022 | |
| Esperion Therapeutics, INC. | $14.45 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $14.32 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Jariwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.